11032021.jpg)
Our collaboration partner Ncardia is offering iPSC-derived cells for Assays on Nanion's Instruments
Ncardia believes that stem cell technology will help to get better medicines to patients faster. Ncardia develops produces & commercialises highly predictive human cellular assay systems for safety and efficacy testing. The cardiac product portfolio encompasses a broad panel of hiPSC-derived cardiac and neural cell types. In addition, the company delivers the Cardioplate™ product line of quality controlled ready to use assay plates. Ncardia delivers working assay solutions & extensive support.
The following cells were validated on Nanion's Instruments:
Cardiac cells
In order to translate an in vitro cardiac cellular model into the correct clinical interpretation of assay read-outs, a fully functional and validated model is needed. This is assured by all of our cardiomyocytes which are fully functional human iPSC-derived cardiomyocytes produced under a stringent quality manufacturing system.
Neural cells
Ncardia’s neural cell portfolio offers 3 relevant cell types that can be used for different structural and functional toxicity assays and CNS disease modeling. All our neural cells have been validated in different morphological and electrophysiological assays. Below you can find an overview of our neural cell types derived from human induced pluripotent stem cells (hiPSC).
Collaborative Activities with Ncardia
Cardiotoxicity - "Assessing cardiotoxic risk of anti-cancer agents on Nanion’s CardioExcyte 96"
CardioExcyte 96 Application Note 
(0.6 MB)
Cells were kindly provided by Ncardia and experiments performed by Oliver Reinhardt and Dr. Frauke Alves from the University of Göttingen.
NCX1 - Current traces recorded from Cor.4U Cardiomyocytes, iCell Cardiomyocytes and HEK cells
SURFE2R N1 data and applications:
Cardiac NCX1 was activated using 30 μM Ca2+ on the SURFE2R N1. NCX1 was recorded from Cor.4U® Cardiomyocytes, iCell® Cardiomyocytes2 or overexpressed in HEK cells. The calcium affinity was determined for NCX1 recorded from iCell® Cardiomyocytes2 and HEK cells, shown on the right.
NCX1 - Block by KB-R7943
SURFE2R N1 data and applications:
Cardiac NCX1 expressed in iCell® Cardiomyocytes2, Cor.4U® Cardiomyocytes or HEK cells was blocked by increasing concentrations of KB-R7943.
NCX1 - Block by SEA0400
SURFE2R N1 data and applications:
Cardiac NCX1 expressed in iCell® Cardiomyocytes2 or HEK cells was blocked by increasing concentrations of SEA0400, a specific blocker of NCX.
2019 - High content in vitro cell monitoring effects of adjuvant chemotherapy in breast cancer and cancer treatment-related cardiomyopathy
CardioExcyte 96 poster, SOT Conference 2019 (0.8 MB)
2018 - Combining electrophysiology and contractility recordings for more complete assessment of hiPSC-CMs
SyncroPatch 384PE (a predecessor model of the SyncroPatch 384), 
Patchliner and 
CardioExcyte 96 poster, Europhysiology Meeting 2018 (1.4 MB)
2018 - A Sensor Based Technique for Pharmacological Safety Testing of Cardiac Transport Proteins NCX, NaKATPase and Respiratory Chain Complexes
CardioExcyte 96 and 
SUFE²R 96SE poster, SPS 2018 (1.7 MB)
19.09.2018 | Nanion Technologies and Ncardia Sign Co-Marketing and Support Agreement to enhance Options for Cardiac Researchers
MUNICH, Germany and COLOGNE, Germany, September 19, 2018-- Nanion Technologies GmbH, a leading provider of instrumentation for ion channel drug discovery and screening, and the Ncardia Group, a leading developer, manufacturer, and service provider of human induced pluripotent stem cells (iPSCs) for safety and efficacy testing announced today that they have entered into a joint marketing and sales promotion agreement.
Anika Duenbostell-Schmidt - Statement about the CardioExcyte 96
"I use the CardioExcyte 96 weekly to test substances on our human iPSC-derived cardiomyocytes. It allows me to map, compare and evaluate a wide variety of pharmacological responses with a high degree of reliability and uniformity, and evaluate them through the rapid analysis function."
Anika Duenbostell-Schmidt, Head QC at Ncardia
Ncardia, Cologne, Germany.
2018 - Investigating pain pathways by inhibition of voltage-gated sodium channels
SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) and Patchliner poster, FENS Meeting 2018 (2.5 MB)
2017 - Cardiomyocytes in Voltage Clamp and Current Clamp by Automated Patch Clamp
SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) and Patchliner poster, BPS Meeting 2017 (1.7 MB)
2018 - Cross-site comparison of excitation-contraction coupling using impedance and field potential recordings in hiPSC cardiomyocytes
CardioExcyte 96 publication in Journal of Pharmacological and Toxicological Methods (2018)
Authors:
Bot C.T., Juhasz K., Haeusermann F., Polonchuk L., Traebert M., Stölzle-Feix S.
2018 - Optogenetic control of transiently transfected hiPSC-derived cardiomyocytes for the assessment of drug related cardiotoxicity
CardioExcyte 96 presentation (slide deck) (1.4 MB)
2017 - Cross-site comparison of myocyte phase II compounds on different iPS cardiomyocytes based on CardioExcyte 96 recordings
CardioExcyte 96 presentation (slide deck) (2.2 MB)
2017 - HTS in Cardiac Safety
CardioExcyte 96 presentation (slide deck) (4.0 MB)
Dr. Ralf Kettenhofen - Statement about the CardioExcyte 96
"CardioExcyte 96 is an easy-to-use system, providing impedance-based and MEA-like cardiac safety data from a diversity of stem cell-derived cardiomyocytes, and constitutes an excellent complement to automated patch clamp-based safety screening. Concentration- and time-dependence of a compound’s potential cardiotoxicity can efficiently be obtained where the alteration of beating patterns can give a hint as to which cardiac ion channel(s) is affected, after which detailed electrophysiology investigations can be undertaken. Cardiac network responses offer a comprehensive view of a compound’s safety profile, without having to use in-vivo methods, which saves time, costs and suffering. Further on, the powerful software, used for recordings and analysis, employs comprehensive beat investigation algorithms, displaying detailed beating kinetics in real-time. Data handling and export is straightforward, easy to grasp and yet very, very powerful."
Dr. Ralf Kettenhofen, Head of Laboratory
Ncardia, Cologne, Germany.
2017 - An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities
CardioExcyte 96 publication in Toxicology and Applied Pharmacology (2017)
Authors:
Koci B., Luerman G., Duenbostell A., Kettenhofen R., Bohlen H., Coyle L., Knight B., Ku W., Volberg W., Woska Jr. J.R., Brown M.P.
2016 - Next level toxicity screening: From single channel to overall cell behavior
Orbit mini, CardioExcyte 96 and SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) poster, Meeting of the French Society of Toxinology (SFET) 2015 (0.9 MB)
2016 - Automated Patch Clamp Meets High-Throughput Screening: 384 Cells Recorded in Parallel on a Planar Patch Clamp Module
SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) publication in Journal of Lab Automation (2016)
Authors:
Obergrussberger A., Brüggemann A., Goetze T.A., Rapedius M., Haarmann C., Rinke I., Becker N., Oka T., Ohtsuki A., Stengel T., Vogel M., Steindl J., Mueller M., Stiehler J., George M., Fertig N.
2015 - Novel screening techniques for ion channel targeting drugs
Patchliner, SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) and CardioExcyte 96 publication in Channels (2015)
Authors:
Obergrussberger A., Stölzle-Feix S., Becker N., Brüggemann A., Fertig N., Möller C.
2013 - Automated Planar Patch Clamp
Patchliner book chapter in Ion Channels (2013)
Authors:
Milligan, C. J., Möller, C.
2013 - Minimized cell usage for stem cell-derived and primary cells on an automated patchclamp system
Patchliner publication in Journal of Pharmacological and Toxicological Methods (2013)
Authors:
Becker N., Stoelzle S., Göpel S., Guinot D., Mumm P., Haarmann C., Malan D., Bohlen H., Kossolov E., Kettenhofen R., George M., Fertig N., Brüggemann A.
2015 - New Easy-to-Use Hybrid System for Extracellular Potential and Impedance Recordings.
CardioExcyte 96 publication in Journal of Laboratory Automation (2015)
Authors:
Doerr L., Thomas U., Guinot D.R., Bot C.T., Stoelzle-Feix S., Beckler M., George M., Fertig N.
Neurons - "Peri.4U and Dopa.4U stem cell-derived neurons recorded on Nanion´s Patchliner"
Patchliner application note: (0.6 MB)
Cells were kindly provided by Axiogenesis.
Cardiomyocytes - "Voltage and current clamp recordings of Cor.4U human iPS cell-derived cardiomyocytes on Nanion’s Patchliner"
Patchliner application note: (0.6 MB)
Cells were kindly provided by Axiogenesis.
Cardiomyocytes - "Impedance and EFP recordings of Cor.4U cells using Nanion’s CardioExcyte 96"
CardioExcyte 96 Application Note (1.3 MB)
Cells were kindly provided by Ncardia.
Cardiac Ion Channels - Pharmacology of Sodium Channels
Patchliner data and applications:
Cells (Cor.AT) were kindly provided by Axiogenesis.
The pharmacology of dibucaine was investigated by the application of 0.3, 1, 3, 10 μM in the presence of 10 μM nifedipine (L-type Ca2+-current blocker). Two control additions of nifedipine (10 μM) were made before the addition of increasing concentrations of dibucaine. The IC50 value was determined as 355 ± 40 nM (n=3), which is in accordance with the literature.
Cardiac Ion Channels - Recordings from SC-Derived Cardiomyocytes
Patchliner data and applications:
Cells were kindly provided by Ncardia.
The left picture shows a typical action potential from Cor.At® cardiomyocytes. Whole cell currents recorded in the voltage clamp mode reveal cardiomyocyte-typical ion channels (right). The traces represent mERG-, L-type Ca2+- (blue, block by 50 μM nifedipine), Na+- and K+-currents (from top left to bottom right).
Cardiac Action Potentials - Cor.At® Cells
Port-a-Patch data and applications:
Cells were kindly provided by Axiogenesis
Cor.At® cardiomyocytes are derived from mouse embryonic stem (ES) cells. Whole cell currents recorded in voltage clamp mode reveal cardiomyocyte-typical ion channels (K+, Ca2+ and Na+). Traces on the lower left show prolongation of the action potential upon application of Dofetilide (1 μM).
Download: Application Note
Cardiac Action Potentials - From SC-Derived Cardiomyocytes
Patchliner data and applications:
Cells were kindly provided by Ncardia.
Action potentials recorded from stem-cell derived cardiomyocyetes (Cor.At® cardiomyocytes). Action potentials are triggered by small current pulses. Effects of quinidine and lidocaine on the action potentials are shown.
Cardiomyocytes - "Recordings of action potentials in mouse ES cell-derived Cor.At cardiomyocytes on Nanion's Patchliner"
Patchliner application note: (0.7 MB)
Cells were kindly provided by Axiogenesis.
Cardiomyocytes - "Action Potentials in Mouse ES Cell-Derived Cor.At Cardiomyocytes on Nanion´s Port-a-Patch"
Port-a-Patch application note: (0.6 MB)
Cells were kindly provided by Axiogenesis.
Cardiomyocytes - Data from different cell providers
CardioExcyte data and applications:
Cells were kindly provided by FUJIFILM Cellular Dynamics, Nexel, Ncardia, Axiogenesis, Pluriomic, GE Healthcare, ReproCell, Takara Bio Cellartis Clonetech.
The CardioExcyte 96 allows for
• Non-invasive, label-free measurements of beating cardiomyocyte networks
• 96 recording wells in parallel with 1 ms time resolution
• Quick experiments or long-term compound effects on cardiotoxicity
• Real-time access to beating parameters
• Outstanding software for data analysis and export
• Cost effcient consumables - 96-well format
Cardiomyocytes - Time-dependent effect of Pentamidine on Cor.4U cardiomyocytes
CardioExcyte data and applications:
Cells were kindly provided by Axiogenesis.
Time-dependent effect of Pentamidine on Cor.4U cardiomyocytes. Pentamidine clinically causes acquired long QT syndrome, which is associated with prolonged QT intervals, tachycardias, and sudden cardiac arrest. Pentamidine delays terminal repolarization in human heart by acutely blocking cardiac inward rectifier currents. At the same time, it reduces surface expression of the cardiac potassium channel IKr/human ether à-go-go-related gene (hERG).
Insets: EFP raw traces and online analysis value FPDc in the presence of Pentamidine (10 µM) at different timepoints.
Cardiomyocytes - Tetracaine dose response curves as recorded with Cor.4U cells
CardioExcyte data and applications:
Cells were kindly provided by Axiogenesis.
Impedance amplitude is not changed by addition of increasing concentrations of Tetracaine (left panel), while beat rate of Cor.4U® cells is decreasing. For example, 29.6µM of Tetracaine decreased the beat rate by ~60% when compared to pre-addition values. Cumulative dose-response relationships indicate Tetracaine potency for same-well additions. Representative raw traces for impedance signals (middle panel) clearly indicate a decrease in cell monolayer beat rate with increasing concentrations of Tetracaine.
Extracellular Field Potential (EFP) spike amplitude is decreased by cumulative Tetracaine dose applications to the same monolayer of Cor.4U® cardiomyocytes (top right), in agreement with compound mechanism of action. Representative raw traces for EFP signals (bottom graph) clearly indicate a decrease in spike amplitude.
Cardiomyocytes - Nifedipine and its concentration dependent effect on Cor.4U cells
CardioExcyte data and applications:
Cells were kindly provided by Axiogenesis.
Nifedpinie is a dihydropyridine calcium channel blocker that primarily blocks L-type calcium channels. Impedance and EFP recordings on Cor.4U cells reveal a concentration dependent effect on impedance amplitude, beat rate and also a shortening of the FPD as expected.
Cardiomyocytes - Optogenetics meets cardiac safety
CardioExcyte data and applications:
Cells were kindly provided by Axiogenesis.
The stimulating optical lid, CardioExcyte 96 SOL, uses LEDs for spatially uniform stimulation of cells transfected with light-gated ion channels such as Channelrhodopsin2 (ChR2).
Right graph: LPM – Light pulse per minute plotted against the recorded beat rate (average of 96 wells). ChR2 transfected Cor.4U cells are following the optical pace rate.
Cardiomyocytes - Channelrhodopsin 2 (ChR2) transfected Cor.4U cells and optical pacing
CardioExcyte data and applications:
Cells were kindly provided by Axiogenesis.
ChR2 transfected Cor.4U cells are following the optical pace rate.
Raw data traces upon a 1 Hz, 1.5 Hz, 2 Hz., 2.5 Hz and 3 Hz stimulation rate, extracellular field potentials (top) and impedance (bottom).
Cardiomyocytes - Myocyte phase II study: CiPA conform analysis and arrhythmia detection
CardioExcyte data and applications:
Cells were kindly provided by Axiogenesis.
Nanion developed a CiPA conform analysis for the Myocyte phase II study. The feature comes along is included in our CiPA analysis routine. Automated arrhythmia detection is just one highlight out of many when it comes to the CardioExcyte 96 software.